Martek Biosciences — Citigroup Healthy Lifestyles Seminar 2008
21 slides from Martek Biosciences's conference presentation, Sep 16, 2008

Slide 1: Martek Biosciences Investor Presentation
Martek Biosciences Investor Presentation Citigroup Healthy Lifestyles Seminar September 2008

Slide 2: Forward Looking Statements
Sections of this presentation contain forward-looking statements concerning, among other things, expectations regarding future revenue growth, product introductions, production expansion, capital expenditures and gross margins. These statements are based upon numerous assumptions that Martek cannot

Slide 3: Martek Biosciences
Martek discovers, develops and manufactures proprietary innovative products that improve human health and well-being through nutrition. Martek Biosciences

Slide 4: Company Overview
A leading producer of patented nutritional oils including DHA omega-3 and ARA omega-6 DHA + ARA - important for brain and eye development in infants Martek is the global leader in providing DHA omega-3 and ARA omega-6 for use in infant formula DHA - a long-chain omega-3 fatty acid = a "good fat" Exp

Slide 5: Why we need DHA
Why we need DHA Numerous clinical studies and scientific research confirm that DHA is an important nutrient for brain, eye and heart health throughout life DHA is 97% of the omega-3 fats in the brain DHA is 93% of the omega-3 fats in the retina DHA is a key component of the heart Despite the benefit

Slide 6: DHA is Important Throughout Life
DHA is Important Throughout Life Pregnancy Maternal Health & Outcomes Promotes maternal DHA status Increases DHA content of breast milk Promotes fetal brain and eye development Infants & Children Brain & Eye Development and Function Improves visual acuity Promotes cognitive performance Children & Ad

Slide 7: DHA research on brain and heart health
Brain Higher DHA levels are associated with improved listening comprehension and vocabulary skills in preschool children. (Clinical Pediatrics, May 2008) DHA increases levels of a specific protein (LR11) which decreases beta amyloid accumulation in the brain and may play an important role in prevent

Slide 8: 2008 Focus Areas
Increasing revenue Growing infant formula, primarily outside the U.S. Further expanding DHA sales in non-infant formula markets Building the life'sDHA(tm) brand Signing DHA supply agreements Gaining broader distribution of supplements containing life'sDHA(tm) Increase product launches by growing con

Slide 9: Infant Formula Market
28 licensees representing approximately 70% of the worldwide market 95%+ penetration of U.S. market (U.S. = $170m-$190m market opportunity) # of U.S. births has trended up in recent years, with 2007 hitting an all-time high (4.3 million births), slightly surpassing previous highs set during the "bab

Slide 10: Broadening the Use of DHA Nutrition Beyond Infant Formula
Broadening the Use of DHA Nutrition Beyond Infant Formula Prenatal vitamins and supplements Supplements for the general population Food and beverage products Animal food and feeds Initial consumers targeted have been moms and their children, baby boomers, and other health conscious consumers Pharmac

Slide 11: Perinatal Products and Supplements
Perinatal Products and Supplements Prescription prenatal vitamins Dietary Supplements OTC prenatal vitamins Recent product launches in CVS and Walgreen's (#1 and #2 pharmacy chains)

Slide 12: Food and Beverage Market Development Strategy
Replicate the successful infant formula market development strategy Establish long-term partnerships with the market leaders Use of Martek logo on product packaging Leverage the branding and marketing expertise of partners to: Develop the life'sDHA(tm) brand Educate consumers / build awareness of th

Slide 13: Key Product Launches - Food & Beverage
Key Product Launches - Food & Beverage 2008 (YTD) 2007 2006 Stella cake Just Launched!

Slide 14: Food & Beverage Category Expansion
Food & Beverage Category Expansion 2008 2007 2006 Soy beverages Yogurt / yogurt drinks Soy beverages Yogurt / yogurt drinks Fluid milk Fruit juice Baby food Sushi Nutrition bar Chocolate bar Meat Cheese sauce Soy beverages Yogurt / yogurt drinks Fluid milk Fruit juice Baby food Sushi Nutrition bar C

Slide 15: Animal Nutrition
Animal Nutrition Expanding the use of DHA in two distinct market segments: 1) animal nutrition (e.g. feeds for swine, poultry, & equine) and 2) companion animals (e.g. pet foods for cats & dogs) October 2007 - signed a global distribution agreement with U.S.- based Novus International, a $700 millio

Slide 16: Why Martek's life'sDHA?
Higher price than fish oil, but: Sustainability Vegetarian Source (Universal Appeal) Relative Ease of Formulation Real and Perceived Risks of Fish Oil High Quality and Martek's comprehensive array of resources made available to partners in support of developing and marketing products fortified with

Slide 17: New Products In Development
Lower cost delivery forms of DHA DHA food and beverage applications DHA in plants Collaboration agreement for DHA-rich canola oil signed May 2008 with Dow AgroSciences Other high-value products that provide health benefits through nutrition High potency DHA for potential pharmaceutical applications

Slide 18: Production Capabilities
Two Manufacturing Sites Kingstree, SC and Winchester, KY Dual-plant production capacity Capable of both DHA and ARA production Both plants rated "Superior" by AIB FDA inspected DSM - ARA production partner Plants in Capua, Italy and Belvidere, NJ Multinational fine chemical / fermentation company In

Slide 19: Non-Infant Formula Revenue Trend
Non-Infant Formula Revenue Trend $11.5 $22.9 $31- $33 *Company guidance provided 09/04/08. Non-Infant Formula nutritional revenue expecting growth in all segments vs. FY'07 ~40% growth vs. FY'07*

Slide 20: Annual Financial Performance + FY'08 Guidance
FY'04 FY'05 FY'06 FY'07 FY'08E Gross Margin 0.377 0.388 0.36 0.37 0.41 Gross Margin Revenue ($ millions) Gross Margin Non-GAAP EPS* *Excludes restructuring charges, tax gain $349-$353 $1.06- $1.09 Annual Financial Performance + FY'08 Guidance* Infant formula Y/Y growth of 12-13%, up vs. prior guidan

Slide 21: Summary
The global leader in DHA and ARA for infant formula Science in support of lifetime health benefits of DHA continues to grow International growth opportunities in infant formula, and DHA gaining traction in food and beverage, perinatal products and supplements markets Existing assets/infrastructure c
Source: SEC EDGAR · 8-K filed Sep 16, 2008
More decks from Martek Biosciences Corp
Canaccord Genuity Growth Conference 201016 slides · Aug 9, 2010
Investor Day (March 2010)39 slides · Mar 5, 2010
Merger or Acquisition (January 2010)15 slides · Jan 21, 2010
Deutsche Bank 32nd Annual Health Care Conference (May 2007)21 slides · May 2, 2007
Investor Presentation (May 2004)15 slides · May 21, 2004